Author Correction: Accurate long-read sequencing identified GBA1 as major risk factor in the Luxembourgish Parkinson’s study (npj Parkinson's Disease, (2023), 9, 1, (156), 10.1038/s41531-023-00595-w)

npj Parkinson’s Disease, published online 23 November 2023 In this article the wrong Table appeared as Table 3.; the Table should have appeared as shown below. The original article has been corrected. The following text that describes data from the previous version of Table 3 has also been removed: “Compared to severe (6.4 ± 4.7) and risk (4.4 ± 4.9) variant carriers, the mild (1.7 ± 1.4) variant carriers show a significantly shorter disease duration (Table 3).” (Table presented.) Features All pathogenic variants (n = 67) Severe (n = 21) Mild (n = 7) Risk (n = 39) Non carriers (n = 554) AAA, mean (SD) 66.5 (±10.2) [OR = 0.31; p = 0.3977] 65.1 (±10.2) [OR = 0.08; p = 0.292] 67.1 (±15.6) [OR = 0.59; p = 0.8959] 67.1 (±9.2) [OR = 0.57; p = 0.7512] 67.6 (±10.7) Sex, Male n (%) 40 (59.7%) [OR = 0.71; p = 0.1912] 13 (61.9%) [OR = 0.78; p = 0.5795] 5 (71.4%) [OR = 1.19; p = 0.8336] 22 (56.4%) [OR = 0.62; p = 0.151] 375 (67.7%) AAO, mean (SD) 61.6 (±11.5) [OR = 0.35; p = 0.484] 58.6 (±13.1) [OR = 0.02; p = 0.1158] 65.4 (±17.0) [OR = 16.16; p = 0.5308] 62.5 (±9.3) [OR = 0.9; p = 0.9548] 62.6 (±11.6) AAO < 45, N (%) 8 (11.9%) [OR = 1.74; p = 0.1767] 2 (28.6%) [OR = 5.14; p = 0.0549] 1 (2.6%) [OR = 0.34; p = 0.2907] 40 (7.2%) Disease Duration, mean (SD) 4.7 (±4.8) [OR = 0.79; p = 0.7303] 6.4 (±4.7) [OR = 4.07; p = 0.2238] 1.7 (±1.4) [OR = 0.04; p =0.0981] 4.4 (±4.9) [OR = 0.57; p = 0.5103] 5.0 (±5.2) Family History, N (%) 8 (38.1%) [OR = 1.8; p = 0.2001] 2 (28.6% [OR = 1.17; p = 0.8508] 15 (38.5%) [OR = 1.83; p = 0.0782] 141 (25.5%).